UNITY-2: Daclatasvir/Asunaprevir/Beclabuvir ± RBV for HCV Genotype 1 With Cirrhosis
Background: The presence of cirrhosis in patients with chronic HCV infection can reduce response to HCV therapies; potent and well tolerated oral regimens are needed. The all-oral DCV-TRIO regimen includes daclatasvir (DCV; pangenotypic NS5A inhibitor), asunaprevir (ASV; NS3 protease inhibitor), and beclabuvir (BCV; non-nucleoside NS5B inhibitor) in a fixed-dose combination (FDC). We evaluated this regimen,…